nav-left cat-right
cat-right

Therapeutic Opportunities for Dry Powder Inhalatio...

Greystone Associates Analyzes Technology and Therapeutic Factors (Amherst, NH) – The convergence of socioeconomic and technology factors – the growing emphasis on drug self-administration for chronic conditions, the expected acceleration in protein- and peptide-based therapeutics, the availability of innovative inhaler device designs – is driving interest in pulmonary drug delivery technology and devices...

Microplate Instrument Trends

This market report summarizes the results of a comprehensive global Pharma/Biotech web-based survey on microplate instrumentation trends carried out in May 2005. The main survey looked at the factors that currently limit productivity from a microplate instrumentation perspective; current and future use of microplate detection instruments and microplate readouts; liquid handling for bulk reagent dispensing and sample addition;...

Xceleron and Servier Sign Collaborative Agreement ...

YORK, Scotland, December 7, 2005 – Xceleron, the bioanalytical CRO who has pioneered human Phase 0 microdose studies and Servier, a French pharma company, announce today that they have signed a twelve-month rolling Collaborative Agreement. The Agreement covers the provision by Xceleron of accelerator mass spectrometry (AMS) services to assist Servier in taking candidate drugs into humans much earlier than conventional...

Beyond the Blockbuster Drug: Strategies for nicheb...

The blockbuster model now delivers just 5% return on investment and only one in six new drug prospects will deliver returns above their cost of capital. As a result competitive pressures and falling R&D productivity will instigate a new pharmaceutical model that replaces the unsustainable blockbuster model; personalized medicine and the “nichebuster”. This report, Beyond the Blockbuster Drug: Strategies for...
Page 16 of 16« First...1213141516